Detection and Management of Preeclampsia: Current Laboratory Testing and Emerging Biomarkers (Online Course)

(based on 462 customer ratings)

Author: David J. Moffa, PhD
Reviewer: Jenny Camele, MT(ASCP)

See all available courses »

Continuing Education Credits

  • P.A.C.E.® Contact Hours: 2 hour(s)
  • Florida Board of Clinical Laboratory Science CE - General (Clinical Chemistry/UA/Toxicology): 2 hour(s)


  • Define preeclampsia (PE)and discuss its prevalence, characteristics, signs, and symptoms.
  • Identify the characteristics of mild and severe PE as well as the relationship to the HELLP Syndrome.
  • Define the risk factors for PE and differentiate between eclampsia and the HELLP Syndrome.
  • Describe the pathophysiology of PE, its cause, treatment, and prevention.
  • Describe the main triggers used to diagnose PE.
  • Identify laboratory tests used to assist in the diagnosis of PE.
  • Define and describe angiogenesis relative to its possible role in PE and associated pro-angiogenic and anti-angiogenic factors.
  • Describe the various potential biomarkers for identifying pregnant women at risk for PE.
  • Identify assay methods available for several potential biomarkers.

Customer Ratings

(based on 462 customer ratings)

Course Outline

  • Background and Overview of Preeclampsia
      • Background and Overview
      • Which of the following statements is NOT true in describing preeclampsia (PE)?
      • True or False. PE affects 5-10% of pregnant women and typically occurs after 20 weeks' gestation.
  • Classification and Characteristics of Preeclampsia
      • Classification and Characteristics of Preeclampsia (PE)
      • HELLP Syndrome
      • Which of the following can be defined as the presence of hypertension (blood pressure >= 140/90) on two occasions at least six hours apart?
      • What condition NOT attributable to any other disorder is associated with eclampsia?
      • Which statement is TRUE regarding the HELLP syndrome?
  • Risk Factors for Preeclampsia
      • Risk Factors for Preeclampsia (PE)
      • Which of the following are considered risk factors for PE?
  • Pathophysiology of Preeclampsia
      • Pathophysiology of Preeclampsia (PE)
      • Doppler Ultrasonography of Uterine Arteries
      • The pathophysiology of PE may be attributable to endothelial cell dysfunction in the ________________.
  • Treatment and Prevention
      • Treatment and Managment of Preeclampsia (PE)
      • Treatment and Management of PE, continued
      • Postpartum PE
      • True or false? The only cure for PE is delivery of the baby.
  • Current Laboratory Testing Used for PE Workup
      • Laboratory Tests Used for PE Workup: Urine and Serum Chemistry
      • Laboratory Tests Used for PE Workup: Hematology and Coagulation
      • Which lab tests listed below are typically performed to assist in the diagnosis of PE, establish baseline levels early in the disorder, and monitor fo...
  • Emerging Biomarkers for Preeclampsia
      • Emerging Biomarkers to Identify Risk for Preeclampsia (PE)
      • Angiogenesis and Angiogenic Biomarkers
      • Table I: Circulating Levels of Angiogenic Biomarkers in Preeclampsia (PE)
      • Table II: Circulating Levels of Other Potential Biomarkers in Preeclampsia (PE).
      • Laboratory Methods for Quantitation of Biomarkers Used for Determining Risk of PE
      • Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels.
      • What statements are TRUE concerning angiogenesis and angiogenic biomarkers?
      • PIGF acts as a vasodilator increasing the diameter of existing arteries, and its serum levels have been found to be significantly lower in mild and se...
      • Choose the correct answer regards the circulating levels of sFlt-1, sEng, and the sFlt-1/PIGF ratio in pregnant women with preeclampsia (PE).
      • Which potential preeclampsia (PE) biomarker that is decreased in PE can be described as a glycoprotein, which is derived from the trophoblast cells an...
      • Which potential PE biomarker is a cell surface molecule expressed by platelets and endothelial cells and circulating levels are increased in PE?
  • Summary and Conclusions
      • American College of Obstetricians and Gynecologists (ACOG) Current Guidelines for Identifying Preeclampsia
      • Summary and Conclusions on the Clinical Use of Biomarkers for Diagnosing and Predicting Risk for Developing PE
      • National organizations such as ACOG typically do not include the use of biomarkers in the practice guidelines for diagnosing and identifying women wit...
      • What conclusions can be made regarding the clinical use of biomarkers to identify and diagnose PE?
  • References
      • References

Additional Information

Level of instruction: Intermediate

Intended Audience: Medical laboratory scientists, medical technologists, and technicians. This course is also appropriate for medical laboratory science students and pathology residents.

Author information: David Moffa, PhD, has over 30 years of experience in the health care industry as an executive manager, clinical laboratory director, and medical laboratory scientist. He is currently a technical consultant for Kentmere Healthcare, Wilmington, DE, and until his retirement, was the Regional Director for LabCorp, Inc. He holds a PhD in medical biochemistry from the School of Medicine, West Virginia University.

Reviewer information: Prior to her retirement in 2012, Jenny Camele was employed by Laboratory Corporation of America as the manager of customer service operations for the Fairmont West Virginia Region and a Quality Assurance committee member. She holds a Bachelor of Science degree in Medical Technology from West Virginia University.

Detection and Management of Preeclampsia: Current Laboratory Testing and Emerging Biomarkers Keywords

These are the most common topics and keywords covered in Detection and Management of Preeclampsia: Current Laboratory Testing and Emerging Biomarkers:

endothelial placental eclampsia liver vessels toxemia ultrasonographic elisa coagulation-related platelets anti-angiogenic immune fetus clinician diagnosis adam-12 gestation ratio abnormal plgf sensitivity biological pecomments trimester dysfunction hypertensive trophoblasts papp-a thromboplastin prenatal nutrient diseases vasodilator preeclamptic soluble disease pp-13 acog cure transforming obstetricians glucose hellp samples p-selectin glycoprotein seizures pro-angiogenic perinatal postpartum concentration preeclampsia hypertension diabetes vitamins angiogenesis laboratory pigf serum angiogenic clinicians systolic arteries embryonic fms-like protein edema identification assessment resolves endoglin health endothelium biomarkercharacteristics vegf factor-beta urine new-onset hemolysis fetal unborn implantation sflt-1 identifying morbidity kinase pregnancies symptoms pregnancy-induced uterine cytotrophoblastic pregnancy ischemia pathogenesis doppler remodeling seng blood cells circulating gestational plasma conditions biomarker occasions tyrosine placenta platelet syndrome proteinuria disorders assays diastolic uterus trophoblast management treatment pregnant guidelines kidney diagnosing clinical pathophysiology pro- coagulation ultrasonography diagnose inflammatory foundation biomarkers trimesters

schistocytes arrows

burr cells arrows

indirect Elisa final

sandwich ELISA

question polychromatophilic RBCs